After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

In the early hours of September 14, 2021, three men parked in a quiet car park in the southern English market town of ...

In the early hours of September 14 2021, three men parked in a quiet car park in the southern English market town of Abingdon-on-Thames.

New synthetic opioids (NSOs) are one of the fastest-growing groups of new psychoactive substances around the world ...

In the early hours of September 14 2021, three men parked in a quiet car park in the southern English market town of Abingdon-on-Thames. The men ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

If Fierce Pharma Marketing’s annual list of the top 10 biggest potential drug launches of the coming year is any indication, ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

Plus: A new non-opioid painkiller, the wave of lawsuits against Trump EOs, a key vote for RFK Jr., a big radiopharma deal and more.

The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

Federal lawmakers are trying once again to push for a study on the “overmedication” of veterans by Department of Veterans ...

As shares of Boston-based Vertex shot higher on the news of its non-opioid pill, Journavx, we took a look at investment in ...